Personalis (PSNL) Q3 2024 earnings summary

Executive summary

• Achieved Q3 2024 revenue of $25.7 million, up 41% year-over-year, driven by 96% biopharma revenue growth and strong MRD product adoption.

• Raised full-year 2024 revenue guidance due to accelerating growth and strong biopharma performance.

• Delivered 945 molecular tests in Q3 2024, a 68% sequential increase, reflecting growing physician adoption.

• Cash balance of $143.7 million at quarter-end extends runway into H1 2027.

• Raised $62.2 million in capital during Q3 via Tempus warrant exercise, equity investment, and ATM sales.

Financial highlights

• Gross margin expanded to 34% in Q3 2024, up from 19.1% a year ago, driven by favorable mix and operating leverage.

• Operating expenses decreased to $23.1 million from $34.3 million year-over-year, reflecting headcount reductions and lower facility costs.

• Net loss was $39.1 million in Q3 2024, including a $26 million non-cash warrant expense.

• Pharma testing/services revenue: $15.7 million (+96% YoY); Enterprise revenue: $5.3 million (-33% YoY); Population sequencing: $4.4 million (+85% YoY).

• Cash, cash equivalents, and short-term investments: $143.7 million as of September 30, 2024.

Outlook and guidance

• Increased full-year 2024 revenue guidance to $83–$84 million, up from prior $79–$81 million.

• Q4 2024 revenue expected to decline sequentially to $15–$16 million due to lower Moderna, Natera, and VA MVP contributions.

• Net loss for 2024 projected at ~$85 million, including ~$18 million non-cash warrant expense.

• Cash usage for 2024 expected at $53–$55 million, improved from prior guidance.